Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Robert F, Jacob"'
Publikováno v:
Journal of Cardiovascular Pharmacology
Eicosapentaenoic acid (EPA) is a triglyceride-lowering agent that reduces circulating levels of the apolipoprotein B (apoB)-containing lipoprotein particles small dense low-density lipoprotein (sdLDL), very–low-density lipoprotein (VLDL), and oxidi
Publikováno v:
Biomedicinepharmacotherapy = Biomedecinepharmacotherapie. 103
The endothelium exerts many vasoprotective effects that are largely mediated by release of nitric oxide (NO). Endothelial dysfunction represents an early but reversible step in atherosclerosis and is characterized by a reduction in the bioavailabilit
Autor:
Robert F. Jacob, R. Preston Mason
Publikováno v:
Springer Series in Biophysics ISBN: 9783319666006
Cellular membranes are dynamic structures that play a critical role in facilitating and maintaining cell function. Membrane structure and fluidity are dependent on relative lipid (including cholesterol) and protein levels, which are known to change w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccc95d460a49cfc575658a8ce86943bc
https://doi.org/10.1007/978-3-319-66601-3_3
https://doi.org/10.1007/978-3-319-66601-3_3
Autor:
R. Preston Mason, Ruslan Kubant, Adam M. Jacoby, Tadeusz Malinski, Febee R. Louka, Robert F. Jacob, J. Jose Corbalan
Publikováno v:
British Journal of Clinical Pharmacology. 74:141-146
AIM Angiotensin II receptor blockers (ARBs) improve endothelial cell (EC)-dependent vasodilation in patients with hypertension through suppression of angiotensin II type 1 receptors but may have additional and differential effects on endothelial nitr
Publikováno v:
Therapy. 8:247-260
Reduced cardiovascular events and mortality have been reported for hypertensive subjects treated with dihydropyridine-type calcium channel blockers (CCBs) and inhibitors of the renin–angiotensin system (RAS) in clinical trials. Recent evidence sugg
Autor:
Timothy J. King, Samuel F. Lockwood, Robert F. Jacob, Tadeusz Malinski, Sanjoy K. Khan, Scott J. Denstaedt, R. Preston Mason, Kazutoshi Fujioka, Fredric J. Pashkow, A. David Hieber, Peter F. Bodary, Thomas H. Goodin, Ruslan Kubant, Henry L. Jackson
Publikováno v:
Thrombosis Research. 126:299-305
Background Cardiovascular disease remains the leading cause of morbidity and premature mortality in most industrialized countries as well as in developing nations. A pro-oxidative state appears to promote and/or exacerbate vascular disease complicati
Autor:
Febee R. Louka, Tadeusz Malinski, Peter T. Malinski, Jan Borowiec, R. Preston Mason, Robert F. Jacob, Yoshiko Mizuno, Xiaoyan Huang, Ruslan Kubant
Publikováno v:
American Journal of Hypertension. 22:1160-1166
BACKGROUND: Endothelial cell (EC) dysfunction contributes to hypertension and mechanisms of atherosclerosis. Agents that improve EC function may provide vascular protection, especially in patients with multiple risk factors. In this study, we examine
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Biomembranes. 1788:1398-1403
Oxidative damage to vascular cell membrane phospholipids causes physicochemical changes in membrane structure and lipid organization, contributing to atherogenesis. Oxidative stress combined with hyperglycemia has been shown to further increase the r
Autor:
Mary Walter, Jan Buch, R. Preston Mason, Barrett W. Jeffers, Prevent Investigators, Yoshiko Mizuno, Robert F. Jacob, Rebekah E. Bjork
Publikováno v:
Journal of the American College of Cardiology. 51(12):1196-1202
Objectives This study was designed to determine the predictive value of lipid hydroperoxide (LOOH) levels for adverse cardiovascular outcomes in patients with stable coronary artery disease (CAD). Background Oxidative modification of circulating lipi
Autor:
Rebecca E Barlag, Ruslan Kubant, R. Preston Mason, Mykhaylo Korda, Philip Funovic, Robert F. Jacob, Tadeusz Malinski
Publikováno v:
Journal of Cardiovascular Pharmacology. 51:208-215
Biological aging is an independent risk factor for many cardiovascular diseases; some are treated with beta-blockers that may protect dysfunctional endothelium during aging by increasing NO, decreasing ONOO, and restoring NO/ONOO balance. A nanotechn